EUCTR2022-003381-21-CZ招募中1 期
Regression of atherosclerosis induced by life changing experience with psilocybin
Psyon, s.r.o.0 个研究点目标入组 60 人开始时间: 2023年5月31日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1) Men and women aged 18-75
- •2) Diagnosis of stable coronary artery disease (I25.9) with a history of myocardial infarction at least 6 weeks before signing informed consent.
- •3) A coronary finding of stenosis on one of the major coronary arteries of at least 2.5 mm in diameter with narrowing that does not exceed 50 % of the reference diameter and is on the native artery without previous intervention.
- •4) Patient's cognitive ability to fully understand CH information and study questionnaires.
- •5) Participants of childbearing age/preserved fertility must agree to use prescribed contraceptive methods and avoid pregnancy while exposed to study medication in this clinical trial. Since both psilocybin and midazolam are eliminated from the body within 24 hours, we are setting the minimum duration of contraceptive use at an interval from enrolment to three days after study drug administration. The following methods of contraception are required:
- •(a) Females – we require proper use of at least a barrier contraceptive method (non-hormonal IUD and/or condom and/or vaginal pessary) or sexual abstinence. Hormonal contraception (combined hormonal contraception - in oral, vaginal or transdermal dosage form/ gestagen hormonal contraception combined with ovulation inhibition - in oral or injectable dosage form/ IUD) is not required but is accepted if the patient is already using)
- •b) Men - use of at least an adequate barrier contraceptive method (condom) or sexual abstinence.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1) Severe neurological disease of the CNS. In case of suspicion of such disease, the CNS imaging (CT/MR) must be negative.
- •2) Focal neurological findings
- •3) Inability to orally administer study medication in capsule form
- •4) Patient's condition does not allow compliance with concomitant therapy (see sections 6.5 and 6.6)
- •5) Known intolerance or allergy to psilocybin or midazolam.
- •6) Pregnancy or breastfeeding
- •7) Hepatic dysfunction with GGT, AST, ALT values > 5 times the upper limit of normal, total bilirubin > 50 µmol/l
- •8) Cardiovascular instability in the sense of uncorrected hypertension (baseline BP = 140/90 mm Hg - mean of 3 measurements), manifest heart failure NYHA II or more, left ventricular ejection fraction < 50%, history of ventricular tachycardia except reperfusion arrhythmias, atrial fibrillation with resting ventricular rate > 100/min (mean of 3 measurements)
- •9) Anatomical findings not allowing IVUS and OCT examination. I.e. tortuous coronary artery, markedly calcified stenosis
- •10) Status post aortocoronary bypass with a functional graft to the artery of interest
- •11) Prior myocardial infarction less than 6 weeks ago with full revascularization
- •12) Prior stroke and/or TIA less than 6 months ago
- •13) Clinically significant peripheral vascular disease (acute venous thrombosis, chronic venous insufficiency at the stage of tibial ulceration, lower extremity ischemic disease at the stage of defects)
- •14) Pulmonary disease with a reduction in vital capacity to 75% of appropriate values, or FEV 1 less than 1.5 l. Sleep apnoea syndrome
- •15) Severe thrombocytopenia < 50 x 109/l, resistant to replacement
- •16) Myasthenia gravis
- •17) Epilepsy including a history of isolated epileptic seizures
- •18) Renal insufficiency with creatinine clearance < 0.6 ml/s
- •19) Known paraneoplastic syndrome or ectopic hormone production by the primary tumour, which could include hypercalcemia, Cushing's syndrome, hypoglycaemia, SIADH, or carcinoid syndrome
- •20) Diabetes mellitus on insulin or corrected with oral antidiabetic agents if there is a history of clinically significant hypoglycaemia
- •21) Glaucoma
- •22) Untreated or incompletely compensated hyperthyroidism
- •23) Use of psilocybin or another serotonergic psychedelic in the past 12 months
- •24) Any current or history of psychotic illness from the diagnosis F2x.x
- •25) Any other serious psychiatric illness based on psychiatric examination
- •26) Stable treatment with antidepressants/thymostabilisers/antipsychotics in a non-hypnotic indication (doses must not be above the antidepressant, antipsychotic or thymostabilising levels as per SPC).
- •27) Presence of suicidal ideation/behavior based on the C-SSRS version of the Lifetime/Recent (L/R) (specifically, a yes response to question 5 in the past 1 month and/or any yes response to suicidal behavior questions in the past 3 months) and/or clinical examination
- •28) Current or history of alcohol or drug dependence F1x.x. unless at least 2 years of abstinence can be demonstrated
- •29) Other inappropriateness of the patient's classification based on the clinical judgment of the examining physician
研究者
相似试验
尚未招募
不适用
Analysis for regression of atherosclerosis in acute coronary syndrome patients after PCSK9 inhibitor therapy by using near-infrared spectroscopy and intravascular ultrasoundJPRN-UMIN000027238Kyoto Prefectural University of Medicine50
已完成
不适用
Prospective observational study of atherosclerosis progression in chronic kidney diseasechronic kidney diseaseJPRN-UMIN000015066Department of Nephrology and Hypertension, Internal Medicine, St. Marianna University School of Medi200
已完成
不适用
Investigation of the progression of atherosclerosis and atherosclerotic risk factor in patients with diabetesDiabetesJPRN-UMIN000014765Division of diabetes, Mitsui Memorial Hospital700
尚未招募
不适用
The association between coronary atherosclerosis and periodontitis: A clinical studyatherosclerosisNL-OMON40327Academisch Medisch Centrum50
招募中
不适用
Targeted Disease Management Plan for Patients with Peripheral Arterial Disease.Peripheral Arterial Disease.Cardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12609000942257ational Health and Medical Research Council (NHMRC)280